Wissenschaftliche Publikationen Suche Suche Autor/in Forschungsgruppe Veröffentlichungsdatum Suchen Sortieren nach RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Reihenfolge AufsteigendAbsteigend Beule, Dieter Dr. (6) Blankenstein, Thomas Prof. Dr. (179) Bunse, Mario Dr. (3) Cakmak-Görür, Nese Dr. (1) Clauß, Julian (1) Daniel, Peter Prof. Dr. (4) Dhamodaran, Arunraj (2) Dyck, Lydia Dr. (1) Filosa, Alessandro Dr. (1) Gerhardt, Holger Prof. Dr. (1) Henssen, Anton Prof. Dr. med. (1) Höpken, Uta Elisabeth PD Dr. (2) Hübner, Norbert Prof. Dr. (1) Ivics, Zoltan Dr. (1) Izsvak, Zsuzsanna Dr. (1) Jeuthe, Sarah Dr. (1) Kammertöns, Thomas Dr. (38) Keller, Ulrich Dr. med. (1) Kieback, Elisa Dr. (3) Kühn, Ralf Dr. (1) Kunz, Severine Dr. (1) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Mertins, Philipp Dr. (3) Na, Il-Kang Dr. (2) Nguyen, Tam Hoai Dr. (1) Obermayer-Wasserscheid, Benedikt Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (17) Poncette, Lucia (4) Popp, Oliver Dr. (3) Rahn, Hans-Peter Dr. (1) Rathjen, Fritz Prof. Dr. (1) Rehm, Armin Dr. (1) Rhein, Simone Dr. (2) Richter, Matthias (1) Rosenberger, Leonie Milena (1) Sawamiphak, Suphansa Dr. (1) Schlag, Peter M. Prof. Dr. (1) Schmitt, Clemens Prof. Dr. (1) Siffrin, Volker (1) Sporbert, Anje Dr. (1) Stein, Ulrike Prof. Dr. (3) Uckert, Wolfgang Prof. Dr. (23) Walther, Wolfgang Prof. Dr. (7) Willimsky, Gerald Dr. (34) Wolf, Susanne Dr. (2) (-) Kopp, Joachim Dr. (5) (-) Leisegang, Matthias Prof. Dr. rer. nat. (10) Genetik und Genomik von Herz- Kreislauferkrankungen (1) Integrative Vaskuläre Biologie (1) (-) Molekulare Immunologie und Gentherapie (15) Translational Bioinformatics (1) 2005 (1) 2006 (1) 2010 (2) 2011 (2) 2013 (1) 2015 (3) 2016 (1) 2017 (1) 2018 (1) 2020 (1) 2022 (1) 15 Ergebnisse: Active Filter: Kopp, Joachim Dr.Leisegang, Matthias Prof. Dr. rer. nat.Molekulare Immunologie und Gentherapie Sortieren: Treffgenauigkeit Neueste nach älteste Älteste nach neueste 01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert 28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein 15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner 15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann 08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel 01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto 01. August 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein 01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber 01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein Seitennummerierung Aktuelle Seite 1 Seite 2 Nächste Seite Next › Letzte Seite Last »
01. März 2010 / Hum Gene Ther Phase I trial of an allogeneic gene-modified tumor cell vaccine (RCC-26/CD80/IL-2) in patients with metastatic renal cell carcinoma A. Buchner H. Pohla G. Willimsky B. Frankenberger R. Frank A. Baur-Melnyk M. Siebels C.G. Stief A. Hofstetter J. Kopp A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. November 2006 / Eur J Immunol Designer T cells by T cell receptor replacement D. Sommermeyer J. Neudorfer M. Weinhold M. Leisegang B. Engels E. Noessner M.H. Heemskerk J. Charo D.J. Schendel T. Blankenstein H. Bernhard W. Uckert
28. Juli 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
15. April 2010 / Clin Cancer Res T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy M. Leisegang A. Turqueti-Neves B. Engels T. Blankenstein D.J. Schendel W. Uckert E. Noessner
15. April 2015 / Int J Cancer Gene expression profiling of peripheral blood mononuclear cells during treatment with a gene-modified allogeneic tumor cell vaccine in advanced renal cell cancer: tumor-induced immunosuppression and a possible role for NF-κB A. Flörcken M. Grau A. Wolf A. Weilemann J. Kopp B. Dörken T. Blankenstein A. Pezzutto P. Lenz G. Lenz J. Westermann
08. Februar 2013 / Mol Med High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination H. Pohla A. Buchner B. Stadlbauer B. Frankenberger S. Stevanovic S. Walter R. Frank T. Schwachula S. Olek J. Kopp G. Willimsky C.G. Stief A. Hofstetter A. Pezzutto T. Blankenstein R. Oberneder D.J. Schendel
01. April 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
01. August 2018 / Clin Cancer Res Targeting Merkel cell carcinoma by engineered T cells specific to T-antigens of Merkel cell polyomavirus I. Gavvovidis M. Leisegang G. Willimsky N.J. Miller P. Nghiem T. Blankenstein
01. April 2015 / Curr Opin Immunol Targeting cancer-specific mutations by T cell receptor gene therapy T. Blankenstein M. Leisegang W. Uckert H. Schreiber
01. April 2015 / Nat Biotechnol Identification of human T-cell receptors with optimal affinity to cancer antigens using antigen-negative humanized mice M. Obenaus C. Leitão M. Leisegang X. Chen I. Gavvovidis P. van der Bruggen W. Uckert D.J. Schendel T. Blankenstein